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Background: Reduced membranous expression of the cytoskeleton-associated protein ezrin has previously been
demonstrated to correlate with tumour progression and poor prognosis in patients with T1G3 urothelial cell carcinoma
of the bladder treated with non-maintenance Bacillus Calmette-Guérin (n = 92), and the associations with adverse
clinicopathological factors have been validated in another, unselected, cohort (n = 104). In the present study, we
examined the prognostic significance of ezrin expression in urothelial bladder cancer in a total number of 442
tumours from two independent patient cohorts.
Methods: Immunohistochemical expression of ezrin was evaluated in tissue microarrays with tumours from one
retrospective cohort of bladder cancer (n = 110; cohort I) and one population-based cohort (n = 342; cohort II).
Classification regression tree analysis was applied for selection of prognostic cutoff. Kaplan-Meier analysis, log rank
test and Cox regression proportional hazards’ modeling were used to evaluate the impact of ezrin on 5-year
overall survival (OS), disease-specific survival (DSS) and progression-free survival (PFS).
Results: Ezrin expression could be evaluated in tumours from 100 and 342 cases, respectively. In both cohorts,
reduced membranous ezrin expression was significantly associated with more advanced T-stage (p < 0.001), high
grade tumours (p < 0.001), female sex (p = 0.040 and p = 0.013), and membranous expression of podocalyxin-like
protein (p < 0.001 and p = 0.009). Moreover, reduced ezrin expression was associated with a significantly reduced
5-year OS in both cohorts (HR = 3.09 95% CI 1.71-5.58 and HR = 2.15(1.51-3.06), and with DSS in cohort II (HR = 2.77,
95% CI 1.78-4.31). This association also remained significant in adjusted analysis in Cohort I (HR1.99, 95% CI 1.05-3.77)
but not in Cohort II. In pTa and pT1 tumours in cohort II, there was no significant association between ezrin expression
and time to progression.
Conclusions: The results from this study validate previous findings of reduced membranous ezrin expression in
urothelial bladder cancer being associated with unfavourable clinicopathological characteristics and an impaired
survival. The utility of ezrin as a prognostic biomarker in transurethral resection specimens merits further investigation.
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In 2008 there were 386 000 estimated new cases of blad-
der cancer in the world, and approximately 150 000 indi-
viduals died from their disease [1]. Bladder cancer is the
fourth most common cancer among men in the USA [2].
Standard treatment for non-muscle-invasive carcinoma
is transurethral resection of the bladder (TURB), with or
without intravesical instillation of bacillus Calmette-Guérin
(BCG), to prevent recurrence and progression. In contrast,
muscle-invasive carcinoma is treated more aggressively
with neoadjuvant chemotherapy and cystectomy [3,4].
However, non-muscle-invasive urothelial carcinoma has a
high risk of recurrence and a substantial risk of progression
[5], and muscle-invasive carcinoma is associated with a
high mortality, despite aggressive treatment [3,6]. Hence,
there is a great need for additional biomarkers to predict
the risk of recurrence and progression into muscle invasive
carcinoma for patients with early stage tumours.
Loss of expression of the membrane-cytoskeletal linking
protein ezrin was initially demonstrated to be associated
with tumour progression and poor prognosis in patients
with T1G3 tumours treated with non-maintenance BCG
(n = 92) [7]. In another recent study comprising 104 tu-
mours of different stages and grades, loss of membranous
ezrin expression was found to correlate with higher grade
and stage, and invasiveness, but the associations with dis-
ease progression and survival were not reported [8]. The
protein ezrin is closely related to two other membrane as-
sociated proteins, radixin and moesin, all three together
named ERM proteins. All these proteins are important for
regulation of cell adhesion and in the linkage between
membrane proteins and the cortical cytoskeleton, thus af-
fecting cell survival, migration and invasion, all factors
contributing to tumour progression and development
[9-11]. ERM proteins are inactive in the cytoplasm, and
activated by binding to the cell membrane [10]. Ezrin is
expressed in a variety of cancers [12] and the prognostic
value of ezrin expression seems to differ in different can-
cer forms. In several cancer forms, high expression of
ezrin has been associated with more aggressive tumours
[13-19], whereas in serous ovarian carcinoma, lost expres-
sion of ezrin correlated with a worse prognosis [20], simi-
lar to the findings in bladder cancer [7].
The aim of this study was to further evaluate the util-
ity of ezrin as a prognostic biomarker in two independ-
ent patient cohorts comprising a total number of 442
cases. Given previous findings of an in vitro interaction
of ezrin with podocalyxin-like protein (PODXL), an
established mediator of metastasis [21], and our recent
results demonstrating that membranous PODXL expres-
sion is an independent predictor of tumour progression
and poor prognosis in urothelial bladder cancer [22], we
also examined the correlations between tumour-specific
expression of ezrin and PODXL.Methods
Patients
Cohort I
This cohort is a consecutive cohort of all patients
with a first diagnosis of urothelial bladder cancer in the
Department of Pathology, Skåne University Hospital,
Malmö, from Oct 1st, 2002 until Dec 31st, 2003, for whom
archival TURB specimens could be retrieved (n = 110). The
cohort includes 80 (72.7%) men and 30 (27.3%) women with
a median age of 72.86 (39.25-89.87) years. Information on
vital status was obtained from the Swedish Cause of Death
Registry up until Dec 31st 2010. Follow-up started at date
of diagnosis and ended at death, emigration or Dec 31st
2010, whichever came first. Median follow-up time was
5.92 years (range 0.03-8.21) for the full cohort and 7.71 years
(range 7.04-8.21) for patients alive (n = 48) at Dec 31st
2010. Fortyeight patients (43.6%) died within 5 years.
The distribution of T-stage was 48 (43.6%) pTa, 24
(21.8%) pT1, 37 (33.8) pT2 and 1 (0.9%) pT3. Eighteen
(16.4%) tumours were Grade I, 34 (30.9%) Grade II and
58 (52.7%) Grade III. The cohort has also been described
previously [22]. Permission for this study was obtained
from the Ethics Committee at Lund University.
Cohort II
This cohort includes 344 patients from a prospective
cohort of patients with newly diagnosed urothelial bladder
cancer at Uppsala University Hospital from 1984 up
until 2005. TURB specimens have been collected retro-
spectively and the predominant group of pTa tumours
reduced to include 115 cases. Progression-free survival
(PFS), overall survival (OS) and disease-specific survival
(DSS) were calculated from the date of surgery to date
of event or last follow-up. Progression was defined as shift
of the tumour into a higher stage. Median time to pro-
gression for patients with non-muscle invasive disease
was 18.0 months (range 2.0-55.0). Follow-up time for non-
recurrent and non-progressing cases were ≥4 and ≥5-years,
respectively. The cohort has been described previously
[22,23]. Permission for this study was obtained from the
Ethics Committee at Uppsala University.
Tissue microarray construction
All tumours were histopathologically re-evaluated and clas-
sified according to the WHO grading system of 2004 by a
board certified pathologist. Tissue microarrays (TMAs)
were constructed as previously described [22,23] using a
semi-automated arraying device (TMArrayer, Pathology
Devices, Westminister, MD, USA). All tumour samples
were represented in duplicate tissue cores (1 mm).
Immunohistochemistry and staining evaluation
For immunohistochemical analysis, 4 μm TMA-sections
were automatically pre-treated using the PT Link system
Figure 1 Sample immunohistochemical images of ezrin
expression. Images (20x magnification) representing tumours with
(A) nearly 100%, (B) approximately 50% and (C) negative ezrin
expression.
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Copenhagen, Denmark) with a polyclonal, monospecific
antibody; HPA021616, Atlas Antibodies AB, diluted 1:1500.
The specificity of the antibody has been confirmed by
immunofluorescence, Western blotting and protein ar-
rays (www.proteinatlas.org). Ezrin expression was anno-
tated in accordance with previous studies [7], whereby
the percentage of cancer cells with membranous pro-
tein sub-localization and the intensity of cytoplasmic
staining, ranging from 0–3 (negative, weak, moderate,
strong), was denoted. When evaluating cytoplasmic
staining the dominating intensity for each core was de-
termined. A mean value of the two samples from each
tumour was used in the statistical analyses. The staining
was evaluated by three independent observers, including
one board certified pathologist, who were blinded to clin-
ical and outcome data and every sample was re-evaluated
once. Omission of primary antibody was used as a nega-
tive control, normal colonic mucosa as positive external
control and lymphocytes as an internal positive control.
Discrepant cases were re-evaluated once again and dis-
cussed in order to reach consensus.
Immunohistochemical expression of PODXL had been
performed as previously described, whereby the presence
of membranous expression was demonstrated to be prog-
nostic [22].
Statistics
Non-parametric Mann–Whitney U or Kruskal-Wallis
tests were applied for analysis of the correlations be-
tween membranous ezrin expression and clinicopatho-
logical characteristics. Classification and regression tree
(CRT) analysis [24] was used to assess optimal prognos-
tic cut-offs for ezrin expression. Receiver operating char-
acteristics (ROC) curve analysis was also applied to
verify the CRT-derived cutoffs. Kaplan-Meier analysis
and log rank test were used to illustrate differences in 5-
year overall survival (OS) and disease-specific survival
(DSS) in strata according to high and low ezrin expres-
sion. Cox regression proportional hazards modeling was
used to estimate the impact of ezrin expression on 5-
year OS in both univariable and multivariable analysis,
adjusted for age, sex, T-stage and grade. All tests were
two sided. P-values <0.05 was considered significant.
All statistical analyses were performed using IBM SPSS
Statistics version 20.0 (SPSS Inc., Chicago, IL, USA).
Results
Distribution of ezrin expression and its association with
clinicopathological characteristics
Following antibody optimisation and staining, ezrin ex-
pression could be evaluated in tumours from 100/110
(90.9%) cases in Cohort I and 342/344 (99.4%) cases in
Cohort II. Lost cases were either a result of completetissue loss during IHC preparation or an insufficient
quantity of tumour tissue. Sample IHC images are
shown in Figure 1 and the distribution of membranous
ezrin expression in both cohorts is shown in Figure 2.
There was no obvious heterogeneity regarding mem-
branous or cytoplasmic ezrin expression between dupli-
cate cores.
As shown in Table 1, analyses of the relationship be-
tween membranous staining and established clinicopath-
ological factors revealed strong, significant associations
Figure 2 Distribution of ezrin expression in two independent patient cohorts. Bar charts visualizing the distribution of different percentages
of ezrin expression in (A) cohort I (n = 100) and (B) cohort II (n = 342).
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more advanced T-stage and high grade tumours in both
cohorts (p < 0.001 for all). Moreover, there was a signifi-
cant association between female gender and reduced
membranous ezrin expression in both cohorts (p =
0.040 and p = 0.013). No associations were found be-
tween membranous ezrin expression and age. Cytoplas-
mic ezrin expression was not associated with any
clinicopathological factors or with membranous ezrin
expression (data not shown). In light of the significant
associations of ezrin expression with female sex, the
distribution of grade and T-stage according to sex was
aslo analyzed, whereby it was found that grade did notTable 1 Associations of membranous ezrin expression with cl
independent patient cohorts of urothelial bladder cancer
Cohort I (n = 100)
Factor n (%) Ezrin expression
median (range)
Age
≤ average 46 (46.9) 30.9 (0.0-100)
>average 54 (54.0) 35.0 (0.0-95.0)
Gender
Female 25 (25.9) 10.0 (0.0-90.0)
Male 75 (75.0) 40.0 (0.0-100)
T-stage
Ta 41 (41.0) 75.0 (0.0-100)
T1 22 (22.0) 25.0 (0.0-95.0)
T2-3 37 (37.0) 2.0 (0.0-80.0)
Grade
Low 44 (44.0) 72.5 (0.0-100)
High 56 (56.0) 10.0 (0.0-90.0)
PODXL expression
Negative 78 (78.8) 40.0 (0.0-100)
Positive 21 (21.0) 5.00 (0–70.0)differ by sex in neither cohort and that the distribution
of T-stages was equal in both sexes in cohort I, but not
in cohort II, where stage II-IV tumours were more
common in women (p = 0.030).
Reduced ezrin expression was also significantly associated
with the presence of membranous PODXL expression in
both cohorts (p < 0.001 and p = 0.009).
Impact of membranous ezrin expression on survival
CRT analysis determined optimal prognostic cut-offs at
17.5% and 27.5% positive ezrin expression in cohort I
and II, respectively, for 5-year OS in cohort I and II
(Additional file 1A and 1B). In cohort II, an optimalinicopathological and investigative parameters in two
Cohort II (n = 342)
n (%) Ezrin expression
p-value median (range) p-value
0.222 157 (45.9) 10.0 (0.0-100) 0.136
185 (54.1) 10.0 (0.0-100)
0.040 82 (24.0) 5.00 (0.0-90.0) 0.013
260 (76.0) 10.0 (0.0-100)
<0.001 115 (33.6) 30.0 (0.0-100) <0.001
116 (33.9) 10.0 (0.0-95.0)
111 (32.5) 0.0 (0.0-60.0)
<0.001 82 (24.0) 40.0 (0.0-100) <0.001
260 (76.0) 5.0 (0.0-95.0)
<0.001 306 (89.7) 10.0 (0.0-100) 0.009
35 (10.2) (0.0-0.80)
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same optimal prognostic cutoffs were obtained by ROC
analysis (data not shown).
As demonstrated in Figure 3, loss of ezrin expression
was significantly associated with a reduced 5-year OS in
cohort I (logrank p < 0.001, Figure 3A) and in cohort II
(logrank p < 0.001, Figure 3B). In cohort II, low ezrin ex-
pression was also significantly associated with an im-
paired DSS (logrank p < 0.001, Figure 3C).
The associations between ezrin expression and survival
were confirmed in unadjusted Cox regression analysis
(Table 2). In adjusted analysis, reduced ezrin expression
remained an independent predictor of a significantly re-
duced 5-year OS in Cohort I (HR = 1.99 (95% CI = 1.05-
3.77). In cohort II, however, loss of ezrin expression did
not remain prognostic after adjustment for established
prognostic factors, neither for 5-year OS nor for DSS
(Table 2).
Given the strong association between reduced ezrin
expression and the presence of membranous PODXL ex-
pression, previously demonstrated to be an independent
factor of tumour progression and an impaired survival
in the herein investigated cohorts [22], we also com-
pared the prognostic ability of ezrin and PODXL in the
multivariable model. This revealed that inclusion of
PODXL did not alter the prognostic value of ezrin ex-
pression, that was retained in Cohort I but not in Cohort
II, neither for 5-year OS nor DSS. Of note, PODXL
remained an independent prognostic factor in Cohort II,
for both 5-year OS and DSS, but not in cohort I (data
not shown).
Since the only previous study on the prognostic value
if ezrin expression in bladder cancer was performed onFigure 3 Kaplan-Meier estimates of bladder cancer specific survival a
survival in (A) cohort I and (B) cohort II, and (C) disease-specific survival intumours from patients with T1 tumours [7], the prog-
nostic value of ezrin expression in subgroups according
to T-stage was also examined. However, ezrin expression
was not found to be prognostic in any particular T-stage
in neither cohort (data not shown). Furthermore, in
contrast to PODXL, reduced ezrin expression was not
significantly associated with time to progression in
non-muscle invasive (pTa and pT1 or pT1) tumours in
cohort II (n = 134 or n = 66, data not shown). Of note,
the number of cases that had received BCG treatment
was only 17 and 7, respectively, in these two patient
categories, hence not allowing for analyses of a potential
treatment predictive effect of ezrin. There was no signifi-
cant association between reduced ezrin expression and a
more frequent rate of recurrence (data not shown).
There were no significant associations between cyto-
plasmic ezrin expression and survival in neither of the
analysed cohorts, and a combined score of cytoplasmic
and membranous ezrin expression did not add prognos-
tic value (data not shown). Since the percentage of
membranous staining was similar between duplicate
cores, use of best or worst score did, as expected, not
improve the prognostic value of ezrin expression (data
not shown).
Discussion
The results from this study demonstrate that loss of
membranous ezrin expression in urothelial bladder can-
cer is strongly associated with a more aggressive tumour
phenotype; i.e. higher grade and more advanced tumour
stage, and an impaired survival. To our best knowledge,
the expression of ezrin in urothelial bladder cancer
has only been described in two previous studies; onend 5-year overall survival. Kaplan-Meier analysis of 5-year overall
cohort II.
Table 2 Relative risks of death from disease and overall death within 5 years according to clinicopathological factors
and ezrin expression in two independent patient cohorts
Cohort I Cohort II
Risk of death within 5 years Risk of death from disease Risk of death within 5 years
Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
n (events) HR (95% CI) HR (95% CI) n (events) HR (95% CI) HR (95% CI) n (events) HR (95% CI) HR (95% CI)
Age
Continuous 100(46) 1.05(1.02-1.08) 1.05(1.02-1.08) 300(100) 1.05(1.03-1.07) 1.05(1.02-1.07) 342(170) 1.06(1.05-1.08) 1.07(1.05-1.08)
Gender
Female 25(11) 1.00 1.00 71(28) 1.00 1.00 82(40) 1.00 1.00
Male 75(35) 0.96(0.49-1.89) 1.12(0.54-2.31) 227(72) 0.79(0.51-1.22) 1.03(0.66-1.61) 260(130) 0.97(0.68-1.38) 1.20(0.83-1.72)
Stage
Ta 41(7) 1.00 1.00 104(13) 1.00 1.00 115(35) 1,00 1.00
T1 22(15) 5.06(2.06-12.46) 2.20(0.73-6.68) 97(25) 2.20(1.13-4.31) 2.17(1.11-4.25) 116(53) 1.63(1.06-2.50) 1.57(1.02-2.40)
T2-4 37(24) 6.15(2.64-14.31) 2.44(0.73-8.19) 97(62) 8.86(4.86-16.16) 8.70(4.76-15.89) 111(82) 4.34(2.91-6.46) 4.36(2.92-6.52)
Grade
Low 44(9) 1.00 1.00 75(7) 1.00 1.00 82(20) 1.00 1.00
High 56(37) 4.71(2.27-9.79) 2.94(1.32-6.53) 223(93) 5.75(2.66-12.39) 1.67(0.64-4.35) 260(150) 3.09(1.94-4.93) 1.20(0.67-2.13)
Ezrin expression*
High 59(19) 1.00 1.00 136(27) 1.00 1.00 120(40) 1.00 1.00
Low 41(27) 3.09(1.71-5.58) 1.99(1.05-3.77) 162(73) 2.77(1.78-4.31) 1.23(0.75-2.02) 222(130) 2.15(1.51-3.06) 1.24(0.84-1.84)
*High and low expression determined by CRT-analysis; cutoff 17.5% for 5-year OS in Cohort I, 27.5% for for 5-year OS in Cohort II and 12.5% for DSS in cohort II.
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non-maintenance BCG [7], and another unselected co-
hort (n = 104). In the former study, while correlations
of ezrin expression with stage and grade could not be
performed, the authors found no associations between
ezrin expression and age, sex, substaging, tumour size,
focality or the presence of CIS, but that reduced ezrin
expression was an independent predictor of progression
into muscle-invasive disease and shorter disease- specific
survival [7]. In the latter study, loss of ezrin was found
to correlate with higher grade and T-stage, and with
muscularis propria invasion, but hazard ratios for risk
of progression or association with survival were not
presented [8].
Thus, the results from our study further validate previ-
ous findings of strong significant associations between
loss of membranous ezrin expression and more ad-
vanced T-stage and high tumour grade in urothelial
bladder cancer. Moreover, this study is the first to report
the prognostic value of ezrin expression in tumours
representing all stages and grades, whereby reduced
ezrin expression was found to be associated with a sig-
nificantly reduced 5-year OS in both examined cohorts,
and with a significantly reduced DSS in cohort II. Of
note, ezrin expression only retained an independent
prognostic value for 5-year OS in the smaller cohort,
and neither for 5-year OS nor for DSS in the larger, clin-
ically more well-characterized, cohort. Therefore, furthervalidation of the prognostic value of ezrin expression in
additional patient cohorts is warranted. Nevertheless,
since tumour stage may be difficult to determine in
TURB-specimens, the strong link between loss of ezrin
expression and advanced tumour stage found here indi-
cates that assessment of ezrin may be an important sur-
rogate marker for bladder cancer patients at risk of
having progressive disease.
In contrast to the findings by Palou et al. [7], we were
not able to demonstrate an association between reduced
ezrin expression and risk of progression into muscle-
invasive disease in pTa-pT1 or pT1-tumours (informa-
tion only available in cohort II). It should however be
pointed out that the number of patients having received
BCG-treatment in our study was too small, and since all
patients in the study by Palou had received non-
maintenance BCG-treatment [7], a potential treatment
predictive effect of ezrin cannot be ruled out, and should
be taken into consideration in future studies.
The observed significant association between reduced
ezrin expression and female sex in both cohorts is note-
worthy, not least since the distribution of tumour grades
did not differ between sexes in any of the cohorts, and a
significant association between female sex and more ad-
vanced T-stage could only be found in cohort II. While
the risk of bladder cancer is considerably higher in men,
there is data indicating an impaired survival from blad-
der cancer in women [25]. These findings indicate that
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ies related to the molecular pathological epidemiology of
urothelial bladder cancer, in particular studies addressing
the influence of sex hormones and reproductive factors
on cancer risk and survival.
Despite use of different antibodies for detection of ezrin
expression in the two previous studies [7,8] and the
present, the results were concordant, which further sup-
ports the utility of ezrin as a prognostic and, potentially
treatment predictive, biomarker in urothelial bladder can-
cer. Immunohistochemistry has several advantages com-
pared with other assays, e.g. gene expression analyses,
since it is comparatively cheap, can readily be adopted into
clinical protocols, and, most importantly, allows for as-
sessment of biomarkers in relation to their subcellular lo-
cation. In our study, no prognostic value or correlation
with clinicopathological factors could be demonstrated for
cytoplasmic ezrin expression, which is also in line with
previous findings [7,8]. The lack of prognostic value for
cytoplasmic ezrin expression is also in agreement with the
observation of ERM proteins only being active when
bound to the cell membrane and not when located in the
cytoplasm [10].
The herein observed inverse association between mem-
branous expression of ezrin and PODXL does not provide
evidence of, but may well indicate, a functional link
between these proteins in urothelial bladder cancer.
This hypothesis is further supported by the previously
demonstrated ability of PODXL to form complex with
ezrin in breast and prostate cancer cells in vitro,
thereby inducing phosphorylation of ezrin and changes in
its subcellular location, in turn leading to an increased
migration and invasion [21]. In light of the apparently
contrasting prognostic value and intercorrelation of ezrin
and PODXL expression in urothelial bladder cancer, it will
be of interest to investigate the existence of a negative
functional cooperativity between these proteins in this
cancer form.
Of note, although cutoffs selected by CRT-analysis in
our study varied somewhat between the cohorts and ac-
cording to the endpoint, ranging from 12.5% to 27.5%
membranous positivity, they still landed closely to the
prognostic cutoff determined as the median percentage of
ezrin expression at 20% in the study by Palou et al. [7], al-
though all tumours in their study were pT1G3. A different
approach was used in the study by Athanasopoulou et al.,
where four categories of a combined score of percentage
and intensity of membranous ezrin immunoreactivity was
applied in the statistical analyses [8]. Moreover, in that
study, nearly all (103/104) tumours were reported to have
positive membranous ezrin expression [8]. Future studies,
preferably in the prospective setting, are warranted to de-
termine optimal cutoffs for the potential use of ezrin as a
biomarker in clinical practice.Conclusions
In summary, the results from this study demonstrate
that reduced membranous ezrin expression in urothelial
bladder cancer is associated with more advanced tu-
mours and a reduced survival. These findings suggest
that ezrin may be a useful prognostic biomarker and
possibly aid in tailoring the treatment of patients with
non-muscle-invasive carcinoma of the bladder. Further
studies are warranted in order to confirm the utility of
ezrin as a prognostic biomarker in clinical practice.
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